| INTRODUCTION
Cardiac troponin I (cTnI) is a marker of myocardial injury used in establishing a diagnosis of myocardial infarction (MI). This marker is used in addition to ischemic signs and symptoms, with chest pain being one of the most common symptom. 1 However, certain populations, including elderly, diabetic and female patients, may have atypical presentation, leading to worse prognosis. In these populations, the suspicion of acute coronary syndrome (ACS) leads to troponin testing. [2] [3] [4] [5] Consequently, it is common for patients admitted to the emergency department (ED) to undergo cTnI determination, despite not presenting cardiac-related symptoms, such as chest pain.
Likewise, cardiac arrhythmias are very common in the ED and are a reason for cTnI determination as they may occur in the case of MI and may be associated with chest pain, syncope or palpitations.
Therefore, it is common to request cTnI to rule out ACS in patients with a primary diagnosis of tachyarrhythmia in the ED. Elevated cTnI levels have been described in patients with cardiac arrhythmias not related to ACS, [6] [7] [8] [9] but the long-term prognostic value of this elevation
is not yet known.
| Troponin I
All analyses of cTnI levels were performed using the same immunoassay techniques (cTnI-Ultra Siemens, Advia Centaur) in the same laboratory. The reference limit for the positivity of the cTnI test was >39 ng/L, corresponding to the 99th percentile of a reference control group, with analytical imprecision expressed by a coefficient of variation below 10%. The analytic performance of this assay has been previously validated. 10 cTnI levels were determined at the time of admission and 6 hours later. We recorded the number of cTnI determinations for each patient, the maximum value and the dynamic rise/fall patterns (changes >20% in cTnI levels). Patients with evidence of a dynamic pattern were classified as acute myocardial injury or as type 2 MI, following Saaby's criteria 11 ; those without evidence of a dynamic pattern were considered to have a chronic myocardial injury.
| Events
The primary outcome of the study was all-cause mortality at the 5-year follow-up. The secondary outcomes were readmission rates for HF and for MI and the combination of all-cause mortality and readmission rates for MI or HF at the 5-year follow-up. The follow-up events were obtained from patients' electronic clinical records and death registers.
| Statistical analysis
Continuous variables are reported as median and interquartile range (IQR). Categorical variables are presented as counts and percentages.
The baseline characteristics of patients were compared using the 3 | RESULTS
| Baseline characteristics
A total of 1021 patients were admitted to the ED with a primary diagnosis of tachyarrhythmia between January 2012 and December 2013; of these patients, 222 patients had their cTnI levels tested (21.7%) ( Figure 1 ). The median age was 69 years, and half were male. Of these patients, 73 (32.9%) had elevated cTnI levels. and higher glycemia (143 vs 122 mg/dL, P = 0.043). Of all the patients admitted, 28% of those with elevated cTnI levels needed hospital admission compared to 6% without elevated cTnI levels (P < 0.001).
Hospital mortality was similar in both groups (P = 0.55). There were differences in the need for hospital admission depending on the type of tachyarrhythmia as follows: 85% of patients with VT, 12% with PSVT and 9% with AF/AFL (P < 0.001). The most common type of tachyarrhythmia in the total cohort was AF/AFL in 78.8% of patients, followed by PSVT in 15.3% of patients and VT in 5.9% of patients.
Patients with cTnI elevation displayed higher proportions of VT compared to the group of patients without cTnI elevation (16.4% vs 0.7%, P < 0.001). The main diagnoses for patients with tachyarrhythmia and elevated cTnI levels according to the presence or absence of a dynamic pattern of cTnI were as follows: 29 patients (45%) had type 2 MI; 24 patients (37%) had acute myocardial injury; and 11 patients (17%) had chronic myocardial injury.
| Events
During a median follow-up of 56 months (IQR 49-64), 51 patients died (23%), 21 patients were readmitted for HF (10%), and 5 patients were readmitted for MI (2%). Patients with elevated cTnI levels had a
higher 5-year all-cause mortality (log-rank test P < 0.001) (Figure 2 ), evident 2 years after diagnosis and increasing after that (Table 2 ).
There were no differences in readmission due to HF or MI. In combined events at 5 years, patients with cTnI elevation had a worse prognosis, mainly driven by increased mortality. It is notable that within the first 30 days, there were no differences in mortality or readmissions due to HF between the two groups, and none of the patients were readmitted for MI. Elevated cTnI levels were found to be a marker associated with higher mortality at the 5-year follow-up in the univariate Cox regression analysis (HR: 2.67, 95% CI: 1.54-4.63, P < 0.001), together with other variables, such as age, prior MI, prior HF and initial presentation with syncope, glycemia, eGFR and anemia.
In the multivariate Cox regression analysis, cTnI elevation remained associated with mortality (HR: 1.95, 95%CI: 1.08-3.50, P = 0.026), in addition to age and prior HF ( Table 3 
| DISCUSSION
This study shows that one-third of patients with a principal diagnosis of tachyarrhythmia admitted to the ED had elevated cTnI levels. This group of patients was identified as a high-risk population due to older age, worse cardiovascular risk profile, and higher long-term mortality.
Therefore, cTnI emerges as a biomarker with predictive capacity for mortality in long-term follow-up, conferring utility in the stratification of risk in this population. In the ED, cTnI testing is a common tool used for the diagnosis of MI. However, elevated cTnI levels are frequently encountered in various clinical situations, such as pulmonary thromboembolism, HF, and sepsis and is associated with poor prognosis. [12] [13] [14] In previous studies, it has been shown that a high proportion of patients admitted to the ED present cTnI elevation in clinical contexts other than acute atherothrombotic plaque disruption (type 1 MI) and that this elevation is associated with a worse prognosis in followups. 15, 16 In addition, it has been observed that the prognosis was similar in patients who fulfill diagnostic criteria for type 2 MI and for non-ischemic myocardial injury, being worse compared to patients with type 1 MI. 17 Moreover, patients with cTnI elevation and without chest pain have been found to present higher mortality rates. 18 In addition, when comparing different laboratory troponin testing in patients in the ED without ACS, cTnT, and cTnI elevations have both important prognostic information regarding all-cause mortality. 19 In conclusion, these data indicate that cTnI elevation is a reflection of acute or chronic myocardial injury that is not always attributable to ACS and should be considered an entity in itself.
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FIGURE 2 Kaplan-Meier survival at 5-year follow-up in patients with and without elevated cardiac troponin I levels From a diagnostic point of view, it is possible that a significant proportion of our patients met the diagnostic criteria for type 2 MI or non-ischemic myocardial injury, as described in other works. 6, 10, 21 However, it can be difficult to differentiate between the two as they may coexist. In our study, 83% of the patients with a primary diagnosis of tachyarrhythmia and elevated cTnI showed a dynamic pattern, meeting the criteria for type 2 MI and acute myocardial injury in similar proportions. Nonetheless, during follow-up, short-and long-term prognoses were worse, regardless of the type of myocardial injury.
In patients with a primary diagnosis of tachyarrhythmia, several studies have described the presence of cTnI elevation. Chow et al 22 retrospectively studied 78 patients who attended an ED due to PSVT. Elevated cTnI levels were observed in 37.2% of the patients, which was a proportion similar to that observed in our study, despite the population being younger and with fewer cardiovascular risk factors. In the multivariate analysis, prior coronary heart disease, HR at admission and ventricular dysfunction were predictors of cTnI elevation. At the 4-year follow-up, elevated cTnI levels were associated with an increased risk of the combined event of all-cause death, MI, and cardiovascular readmission (HR: 3.67, 95% CI: 1.22-11.1, P = 0.02). This result was mainly driven by cardiovascular readmissions, unlike the observations in this study. Mariathas et al 23 observed elevated cTnI levels (Beckman Coulter Access) in 46.8% of patients in a retrospective study of patients with different types of primary tachyarrhythmia. Consistent with our results, patients with elevated cTnI levels showed a higher mortality rate compared to patients without cTnI elevation, with mortality rates similar to patients with MI and without ST-segment elevation.
The presence of underlying coronary disease in patients with tachyarrhythmia and elevated cTnI levels has been the subject of controversy and research. In a study by Yedder et al, 24 73 patients with PSVT were analyzed, and 32.9% presented elevated cTnI levels. After carrying out MI detection studies in 9 patients with elevated cTnI levels and in 11 without cTnI elevation, only 1 patient had significant coronary artery disease requiring revascularization. They concluded that tachyarrhythmia is associated with elevated cTnI levels, but less than 10% of these patients show significant severe coronary disease.
This finding is consistent with that of Schueler et al study. 25 They ana- HF patients are predisposed to develop arrhythmias. It has been described that highly complex, interactive, and dynamic changes in mechanical, structural neurohormonal properties might predispose the failing heart to tachyarrhythmias. In our study, there were no differences in the history of HF between the cTnI elevation groups or readmission for HF in the long term, but prior HF was an independent mortality risk factor in the long term. This result may reflect a relationship between tachyarrhythmias and structural changes describing an underlying structural heart disease, which might explain cTnI elevation.
Therefore, the mechanisms justifying elevated cTnI concentrations in tachyarrhythmia may be multiple and influenced by other factors that are not yet fully clear. It is possible that shortening of the diastolic period during tachyarrhythmia leads to the appearance of subendocardial ischemia, which explains the elevation of cardiac biomarkers. 27 Another potential pathophysiological mechanism was described by Goette et al 28 study, several markers of oxidative stress mediated by angiotensin II were increased in pigs subjected to rapid atrial pacing. In other experimental studies, it has been observed that myocardial overdistension represents another tachycardia-dependent mechanism that would justify the troponin elevation, since there is a direct association between the parallel increase in proBNP and troponins. 29 It is also possible that changes in the permeability of the cardiac myocyte membrane secondary to myocardial injury may be sufficient to generate the release of cardiac troponin to the cytoplasm, without structural damage being seen. 30 Thus, overall, it seems very likely that the cause of cTnI elevation in tachyarrhythmia is multifactorial and is more frequent in the elderly population and in patients with multiple cardiovascular risk factors and comorbidities.
Because in our study, the adverse prognosis of patients with elevated cTnI levels was determined on an all-cause basis and not by readmission rates for cardiovascular causes, we consider that the performance of ischemia detection studies should be established individually, according to the pre-test probability of ischemic heart disease and the clinical characteristics of the acute episode. An important potential practical implication of our observations is the expectation of elevated cTnI levels among one-third of patients admitted to the ED with tachyarrhythmias. Thus, our findings suggest that cTnI assessment in these patients could be a useful tool for long-term mortality risk prediction, in parallel to a clinical assessment of conventional risk factors. To date, no interventions have been described that are capable of modifying the adverse prognosis in this population. Hence, close monitoring seems to be the most reasonable therapeutic strategy.
| Limitations
This study has certain limitations. First, cTnI testing in the ED was left to the decision of the treating physician, who may not have measured cTnI in patients with a lower risk perception, such as younger adults with fewer cardiovascular risk factors. This decision could represent a selection bias. Despite this limitation, the study reflects the real-life clinical scenario in the ED. Second, as it was a retrospective study, the evaluation of coronary heart disease was not performed in all patients with elevated cTnI; hence, we cannot draw conclusions on this aspect.
However, in the short-and long-term follow-up, we did not observe readmission for MI or HF. This result strongly suggests that elevated cTnI levels do not correlate closely with the burden of coronary atherosclerotic disease. Third, the study did not aim to identify the mechanism by which elevated cTnI levels predict cardiovascular risk in the context of tachyarrhythmia.
| CONCLUSIONS
This study shows that cTnI elevation in patients with a primary diagnosis of tachyarrhythmia admitted to the ED is frequent and is associated with an increased risk of long-term mortality. These patients presented a worse cardiovascular risk profile and more comorbidities.
Our data prompt the need for more research to understand the mechanisms of elevated cTnI levels in patients with tachyarrhythmia and the association with cardiovascular risk.
